Pro-inflammatory eicosanoid synthesis pathway

The **pro-inflammatory eicosanoid synthesis pathway** is a collective term for the metabolic routes that generate pro-inflammatory lipid mediators known as eicosanoids from polyunsaturated fatty acids, mainly arachidonic acid[2][5][6]. This pathway encapsulates multiple enzyme systems, notably cyclooxygenases (COX-1, COX-2) producing prostaglandins and thromboxanes, and lipoxygenases (LOX, notably 5-LOX) producing leukotrienes[1][2][5]. These products are rapidly synthesized in response to cellular stimuli, such as tissue injury or pathogen exposure, and play central roles in driving inflammation, pain, immune cell trafficking, fever, and vascular changes[1][3][5][7]. While components of these pathways (such as COX-2, 5-LOX, and specific eicosanoid receptors) are established therapeutic targets, the pathway itself represents a functional metabolic network rather than a discrete molecular target or protein; thus, it is not technically a “therapeutic target” in the ordinary sense and should not be listed as a singular molecule or receptor[5][6]. Drug development focuses on inhibition of key enzymes or blockade of eicosanoid receptors to blunt pathological inflammation in a range of diseases, notably autoimmune, cardiovascular, allergic, and some cancers[2][5][7]. **Note:** This entry is **incorrect as a therapeutic “target”**—the pro-inflammatory eicosanoid synthesis pathway is a metabolic pathway comprising multiple enzymes and molecular targets, not a specific molecule, receptor, enzyme, or protein suitable for direct pharmacological targeting. For structured databases, individual components (e.g., Cyclooxygenase-2, 5-Lipoxygenase, Prostaglandin E2 receptor) should be listed as specific targets.

Other names

Pro-inflammatory eicosanoid biosynthesisEicosanoid pathway (pro-inflammatory branch)Prostaglandin synthesis pathwayLeukotriene synthesis pathway

Inhibition of cyclooxygenase enzymes (COX-1, COX-2) Inhibition of lipoxygenase enzymes (LOX family) Blocking eicosanoid receptors Inhibition of phospholipase A2 to prevent arachidonic acid release